Artwork

Content provided by The Wall Street Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Trillion Dollar Shot, Episode 4: The Disruptors

43:00
 
Share
 

Manage episode 422655940 series 2518362
Content provided by The Wall Street Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The rising popularity of GLP-1 drugs could cause all kinds of ripple effects.

According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction.

In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy?

Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health.

Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here.

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

1286 episodes

Artwork
iconShare
 
Manage episode 422655940 series 2518362
Content provided by The Wall Street Journal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The rising popularity of GLP-1 drugs could cause all kinds of ripple effects.

According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction.

In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy?

Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health.

Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here.

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

1286 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide